Guggenheim’s Rohit Vanjani already is bracing for a roughly 50% share loss year-over-year for the Israeli pharma giant by 3Q:18.
RBC Capital’s Randall Stanicky says everything rides on Teva’s power to keep a grip on 2020 revenue.
RBC Capital’s Randall Stanicky wonders how strong is Teva’s long-term value investor support to be able to “absorb” a guidance misstep?
Oppenheimer’s Derek Archila says Teva shares are “not cheap” considering the risk factor of the new cost-cutting plan and headwinds circling.
In the foreseeable future, Maxim’s Jason Kolbert finds it unlikely TEVA will find itself in a place to boost its guidance.
Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) slipped 2% this morning after the generic giant announced that a Phase III registration study evaluating …
A NYT article has Wall Street abuzz today with whispers of non-profit hospital groups creating a new generics maker or partnering with third party manufacturers.
Though BTIG’s Tim Chiang sees a recovery in the works for TEVA, he sees shares as “fairly valued” at currently levels.
Guggenheim’s Rohit Vanjani reacts to the debt rating downgrade on Teva from the sidelines without shock, having seen the writing on the wall.
Goldman Sachs’ Jami Rubin now spotlights 16% return potential for TEVA shares, putting his bet on the Israeli pharma giant’s recovery.
